Table 3.

Toxicity of long-term PX-866 administration

Treatment groupALT (units/L)AST (units/L)Glucose (mg/dL)WBC (K/μL)NE (K/μL)LY (K/μL)MO (K/μL)RBC (M/μL)Hb (g/d)Plt (K/μL)Weight change (g)
Control52.6 ± 13.6142.9 ± 46.646.9 ± 5.18.9 ± 1.06.9 ± 0.81.1 ± 0.20.8 ± 0.111.0 ± 0.315.4 ± 0.21,427 ± 604.7 ± 0.3
PX-866 10 mg/Kg i.v.35.5 ± 11.7105.2 ± 19.276.2 ± 3.614.6 ± 4.214.0 ± 2.71.8 ± 0.51.1 ± 0.210.6 ± 0.014.4 ± 0.11,390 ± 433.9* ± 0.2
PX-866 3 mg/Kg orally47.6 ± 16.8152.0 ± 47.2113.5* ± 23.467.8* ± 19.753.6 ± 10.75.2±3.99.2±3.610.4 ± 0.314.7 ± 0.41,665 ± 2271.3 ± 0.5
PX-866 1.5 mg/Kg orally65.6 ± 27.5140.5 ± 35.2100.1 ± 10.916.6* ± 2.412.5* ± 1.93.1* ± 0.61.8* ± 0.210.30 ± 0.314.6 ± 0.31,221* ± 183.9 ± 0.6
  • NOTE: PX-866 was administered either i.v. or orally as 14 doses every other day to male SCID mice. Twenty-four hours after the last dose, blood was collected for serum chemistry and differential blood counts. Values are the mean of four mice per group ± SE.

    Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; NE, neutrophil; Hg, hemoglobin; Plt, platelet; LY, lymphocyte; MO, monocyte.

  • * P < 0.5.

  • P < 0.01 compared with the control value.